fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Panel debate merits of transplantation

Written by | 8 Oct 2019

In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.

IMW 2019: Relapsed/refractory myeloma: ongoing challenges and emerging hope

Written by | 8 Oct 2019

Article written by Tom Collins. Interview by Esther Drain.

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.

IMW 2019: As treatment options explode, questions remain myriad in myeloma

Written by | 8 Oct 2019

Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.

IMW 2019: Panel debate merits of transplantation

Written by | 8 Oct 2019

Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.

Relapsed/refractory myeloma: ongoing challenges and emerging hope

Written by | 8 Oct 2019

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.

Translational oncology symposium

Written by | 18 Jul 2019

The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.

EHA 2019: CASSIOPEIA study

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Among the clinical studies that reported results at the EHA congress 2019 was part 1 of the CASSIOPEIA study…. read more.

EHA 2019: COLUMBA study

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.

EHA 2019: Late-breaking abstracts at EHA

Written by | 2 Jul 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Oral selective BCL-2 inhibitor venetoclax has demonstrated encouraging clinical efficacy against MM. As monotherapy, venetoclax has shown to be… read more.

Advances in RRMM

Written by | 9 May 2019

Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study

Transplantation, Consolidation and Maintenance

Written by | 8 May 2019

  Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.

Integrating CAR T-Cell therapy into the treatment of myeloma

Written by | 7 May 2019

Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.